Why should you keep an eye on Replimune Group Inc (REPL)?

Replimune Group Inc (NASDAQ: REPL) is -5.69% lower on its value in year-to-date trading and has touched a low of $5.89 and a high of $25.83 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The REPL stock was last observed hovering at around $7.76 in the last trading session, with the day’s gains setting it 0.19%.

Currently trading at $7.95, the stock is 2.32% and -3.46% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.81 million and changing 2.45% at the moment leaves the stock -49.33% off its SMA200. REPL registered -68.84% loss for a year compared to 6-month loss of -60.13%. The firm has a 200-day simple moving average (SMA200) of -$0.49.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -9.76% gain in the last 1 month and extending the period to 3 months gives it a -30.75%, and is 12.77% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.57% over the week and 6.44% over the month.

Distance from 52-week low is 34.97% and -69.22% from its 52-week high. The company has generated returns on investments over the last 12 months (-42.55%).

Replimune Group Inc quarterly earnings per share for the current quarter are estimated at -$0.84.The EPS is expected to shrink by -4.35% this year.

Replimune Group Inc (REPL) Top Institutional Holders

201 institutions hold shares in Replimune Group Inc (REPL), with institutional investors hold 115.36% of the company’s shares. The shares outstanding are 56.68M, and float is at 43.36M with Short Float at 17.18%. Institutions hold 106.89% of the Float.

The top institutional shareholder in the company is Price (T.Rowe) Associates Inc with over 5.73 million shares valued at $133.12 million. The investor’s holdings represent 9.72% of the REPL Shares outstanding. As of Jun 29, 2023, the second largest holder is Baker Brothers Advisors, LLC with 4.58 million shares valued at $106.31 million to account for 7.76% of the shares outstanding. The other top investors are Redmile Group, LLC which holds 4.42 million shares representing 7.49% and valued at over $102.64 million, while Blackrock Inc. holds 5.92% of the shares totaling 3.49 million with a market value of $81.13 million.

Replimune Group Inc (REPL) Insider Activity

A total of 10 insider transactions have happened at Replimune Group Inc (REPL) in the last six months, with sales accounting for 5 and purchases happening 5 times. The most recent transaction is an insider sale by Xynos Konstantinos,the company’sChief Medical Officer. SEC filings show that Xynos Konstantinos sold 7,313 shares of the company’s common stock on Nov 16 at a price of $10.92 per share for a total of $79858.0. Following the sale, the insider now owns 0.11 million shares.

Replimune Group Inc disclosed in a document filed with the SEC on Nov 16 that Sarchi Christopher (Chief Commercial Officer) sold a total of 5,255 shares of the company’s common stock. The trade occurred on Nov 16 and was made at $10.92 per share for $57385.0. Following the transaction, the insider now directly holds 72245.0 shares of the REPL stock.

Still, SEC filings show that on Sep 12, Esposito Pamela (Chief Business Officer) disposed off 300 shares at an average price of $20.00 for $6000.0. The insider now directly holds 263,436 shares of Replimune Group Inc (REPL).

Replimune Group Inc (REPL): Who are the competitors?

The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -3.01% down over the past 12 months. Eli Lilly & Co. (LLY) that is 110.41% higher over the same period.